Mutaciones en el gen BCR-ABL1 en un paciente peruano con leucemia linfoblástica aguda resistente a terapia
DOI:
https://doi.org/10.31053/1853.0605.v74.n2.16463Keywords:
Proteínas de fusión, bcr-abl, Leucemia, Resistencia al tratamiento, Mutación, Análisis de secuenciasAbstract
Introducción: El gen de fusión BCR-ABL1 está presente en al menos la cuarta parte de pacientes adultos con leucemia linfoblástica aguda de células B. Su detección determina la viabilidad del tratamiento con inhibidores de tirosina quinasas (TKIs) que se controla mediante la cuantificación de transcritos de BCR-ABL1. Algunos pacientes no responden o recaen al tratamiento debido a la presencia de mutaciones en el dominio tirosina quinasa del gen BCR-ABL1. Reporte de caso: Se reporta un paciente con BCR-ABL1 que logra una respuesta molecular luego de iniciado la terapia con imatinib; sin embargo, recae después de quince meses cambiándose el tratamiento a dasatinib. El cambio no permitió una respuesta molecular a la terapia. Retrospectivamente, se realizó la búsqueda de mutaciones en el BCR-ABL1 encontrándose tres mutaciones de resistencia a terapia (E459K, E255K y V299L). Conclusiones: La aparición de mutaciones durante el tratamiento con TKIs tiene un fuerte impacto en el progreso de la enfermedad, siendo relevante la búsqueda de mutaciones ante recaída o persistencia de transcritos del BCR-ABL1.
Downloads
References
1. Ghazavi F, Van Roy N, Poppe B, Speleman F, et al. The molecular basis and clinical significance of genetic aberrations in B-cell precursor acute lymphoblastic leukemia. Experimental Hematology. 2015. En impresión.
2. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984; 36:93–9.
3. Maino E, Sancetta R, Viero P, Imbergamo S, Scattolin A, et al. Current and future management of Ph/BCR-ABL positive ALL. Expert Reviews Anticancer Therapy. 2014; 14(6): 723-740.
4. Mitterbauer G, Nemeth P, Wacha S, Cross N, Schwarzinger I, et al. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukemia using quantitative competitive polymerase chain reaction. British Journal of Haematology. 1999; 106:634-643.
5. Ottmann O y Pfeifer H. Management of Philadelphia chromosome– positive acute lymphoblastic leukemia (Ph+ ALL). Hematology. 2009; 371-381.
6. Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinibbased therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110:727-734.
7. Cioch M, Lewandowski K, Gniot M, Dmoszynska A. Complete molecular remission with platelets number normalization after dasatinib therapy in patient with cml complicated by thrombocytopenia and resistant to imatinib due to an E459K mutation. Haematologica 2010; 95[suppl.2]:547, abs. 1357.
8. Jonas D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia. Journal of Molecular Diagnostic. 2009; 11(1): 4-11.
9. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, et al. Activity of Bosutinib, Dasatinib, and Nilotinib against 18 imatinib resistance BCR/ABL mutants. Journal of Clinical Oncology. 2008; 469-471.
10. Leoni V, Biondi A. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):295-299.
11. Aricò M, Schrappe M, Hunger SP, et al. Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. Journal of Clinical Oncology. 2010;28(31):4755-4761.
12. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318-57.
13. Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008; 113:985-994.
14. Pfeifer H, Wystub S, Wassmann B, et al. Minimal residual disease and mutational status prior to and after SCT for patients with philadelphia-chromosomepositive acute lymphoblastic leukemia (Ph+ ALL). 50th ASH Annual Meeting and Exposition. San Francisco, CA. 2008.
15. Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, et al. Solution conformations and dynamics of ABL kinase inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem. 2008;283(26):18292-18302.
16. Sierra J, Cepero V y Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Molecular Cancer. 2010; 9:75
Downloads
Additional Files
Published
Issue
Section
License
Copyright (c) 2017 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The generation of derivative works is allowed as long as it is not done for commercial purposes. The original work may not be used for commercial purposes.
How to Cite
